Lobbying client

SAGHMOS THERAPEUTICS, INC.

Bio-pharmaceutical company

Filings
11
Filed by
1
Reported in-house
—
Reported by firms
$280,000

Reported lobbying by year

The larger of in-house and firm-reported each year, $ thousands 2020 to 2022

Filings

11 filings, newest first.
Filing Filed by Amount
3rd Quarter - Termination (No Activity)
3rd Quarter 2022
CHAMBER HILL STRATEGIES — reported
2nd Quarter - Report (No Activity)
2nd Quarter 2022
CHAMBER HILL STRATEGIES — reported
1st Quarter - Report (No Activity)
1st Quarter 2022
CHAMBER HILL STRATEGIES — reported
4th Quarter - Report
4th Quarter 2021
CHAMBER HILL STRATEGIES $50,000 reported
3rd Quarter - Report
3rd Quarter 2021
CHAMBER HILL STRATEGIES $50,000 reported
2nd Quarter - Report
2nd Quarter 2021
CHAMBER HILL STRATEGIES $30,000 reported
1st Quarter - Report (No Activity)
1st Quarter 2021
CHAMBER HILL STRATEGIES — reported
4th Quarter - Report
4th Quarter 2020
CHAMBER HILL STRATEGIES $50,000 reported
3rd Quarter - Report
3rd Quarter 2020
CHAMBER HILL STRATEGIES $50,000 reported
2nd Quarter - Report
2nd Quarter 2020
CHAMBER HILL STRATEGIES $50,000 reported

Filed by

Each firm that has reported for this client, and the client itself where it lobbies in-house, with the reports filed and the amounts they disclose.

FirmReportsAmount
CHAMBER HILL STRATEGIES 10 $280,000

Issues lobbied

How many report sections named each issue, counting the current version of each report.

IssueCodeMentions
Health Issues HCR 7
Medicare/Medicaid MMM 6

Bills named in its filings

Bill numbers found in the filers' descriptions, most often named first.

BillCongressTimes named
H.R. 6000 117th 1

From reports filed under the Lobbying Disclosure Act. Firms report what each client paid them; an organisation lobbying for itself reports its own expenses. Amounts count the current version of each report once.